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Multiple biological, synthetic and hybrid polymers are used for multiple medical applications. A wide range of different polymers is available,
and they have further the advantage to be tunable in physical, chemical and biological properties in a wide range to match the requirements of
speciﬁc applications. This review gives a brief overview about the introduction and developments of polymers in medicine in general, addressing
ﬁrst stable polymers, then polymers with degradability as a ﬁrst biological function, followed by various other functional and responsive
polymers. It is shown up that biomedical polymers comprise not only bulk materials, but also coatings and pharmaceutical nano-carriers for
drugs. There is subsequently an overview of the most frequently used polymer classes. The main body of the review then is structured according
to the medical applications, where key requirements of the applications and the currently used polymer solutions are indicated.
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The basic principle of polymers, that is multiple assemblies
of simple structural units for the formation of a 3-dimensional
construct, has wide distribution in all biological systems. This
ranges from intracellular ﬁlaments and cytoskeleton via
structural proteins of the soft extracellular matrix and matrices
with mechanical function in ligaments or cartilage to keratin of
skin and hairs at the human surface interface with the
environment and insects can produce silk polymers even for
external constructions. Such natural polymers like horn, hair,
or cellulose have been utilized by human since beginning of
manhood, and they have found application in medicine, e.g. as
suture material also for long time [1].
Man-made synthetic polymers are almost as manifold as the
natural ones, although the most progress in development only
started about in the Second World War. Newly developed
polymers rapidly entered medical application, such as the
polyesters and polyamides as synthetic suture materials.
Synthetic polymers gained high attraction for technical as
well as for medical application for various reasons. A wide
range of physical and chemical properties can be achieved
based on the monomer units, polymerization reaction and
formation of co-polymers consisting of different components
at adjustable concentrations [2]. Technologies for synthesis
and formation also of complex shaped devices are mostly
established. These types of polymers mainly fulﬁll structural
and mechanical properties. Mechanical self-reinforcement is
achieved by integration of oriented ﬁbers of the same material
into the matrix [3,4]. There are also highly advanced mechan-
ical properties, such as shape memory polymers, which can befreely deformed and return to their original shape upon a
special stimulus, which can be pH, temperature, magnetic ﬁeld
or light. They found application in biomedicine in drug
delivery devices, vascular stents, sutures, clot removal devices,
for aneurysm or ductus arteriosus occlusion, and orthodontic
therapy as reviewed elsewhere [5,6].
Besides the mechanical properties also speciﬁc functional
characteristics of polymers are used. Semipermeable mem-
branes of biopolymers (cellulose) or polymers are used for
hemodialysis or as drug delivery systems. Swelling or
collapsing of pores of the membrane in response to pH,
temperature or other stimuli leads to membranes for respon-
sive drug release [7].
Due to their carbon based chemistry, polymers are closer to
biological tissue than inorganic materials. This can be used for
targeted interaction between the material and the body, but may
also cause problems due to an interference of rest-monomers,
degradation-products or additives with biochemical pathways.
Reactive groups in the Polymers usually also offer the possibility
for biofunctionalization of the surface, either because they
provide reactive groups by themselves, or e.g. plasma technolo-
gies can be used to create such groups for covalent anchorage of
molecules on the surface. The surface modiﬁcation techniques
allow independent optimization of the mechanical properties of
the bulk and biocompatibility properties of the surface.
Functional types of polymers evolved for biomedical
applications. Biodegradable polymers ideally stay in the body
only as long as they serve their function and then they
disappear without the need of a second surgical intervention
[8–10]. Orthopedic ﬁxation and ligament augmentation were
the primary motivation for biodegradable polymers [11]. Since
M.F. Maitz / Biosurface and Biotribology 1 (2015) 161–176 163the 1990ies, vascular stents developed as the main target
application [12–16]. These degradable polymers have been
further used for the delivery of drugs along with the degrada-
tion from microcarriers or macroscopic applications [17,18].
Synthetic, hydrolytically degrading polymers are preferred for
many applications as implant or drug release system, because
their degradation is relatively invariant from patient to patient
and for different implantation sites [8,19]. In contrast to this,Polyolefins PTFE
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tion with cell adhesion molecules, and growth factors which all
should support homing, differentiation and proliferation of the
tissue speciﬁc cells [21–23]. Also the stiffness of the scaffold
polymers is adjusted to match the target tissue to support the
appropriate cell differentiation [24].
Polymers which degrade or respond otherwise to environ-
mental conditions gained special attention as functional
materials. Responsiveness to physical stimuli like mechanical
stress [25,26], electricity [27], temperature changes [28,29], or
light irradiation [30,31], and combinations thereof [32,33] can
be used to trigger a drug release by external stimuli. But
polymers also can react on internal chemical and biochemical
triggers like pH [34], drugs, metabolites, antigens or enzyme
concentrations [35–40] and so autonomously respond to a
physiological status. Suitable settings even allow feedback
controlled homeostasis of blood glucose [35], urate concentra-
tion [38] or coagulation [39,41].
In these advanced applications, the polymers are typically not
present as bulk materials. They are formed as coatings on
biomedical devices, or as micro- and nanospheres for targeted
drug delivery. Coatings may be non-structured homogeneous
coatings, crosslinked coatings, polymer brushes or layer-by-layer
deposited ﬁlms. The spherical particles can include solid colloids,
dendrimers, micelles, nanogels, capsules or core–shell particles, as
reviewed elsewhere [42–45].
Despite the current wide spectrum of polymers available in
biomedicine, it is frequently difﬁcult to fulﬁll all requirements of a
device at the same time in a cost efﬁcient way. In addition, there are
inherent problems with some types of polymer: Polymerization
usually is a statistical process, and control of the molecular weight
distribution differs for different reaction chemistries. While the
polymers as such are mainly non-toxic, there are frequent concerns
about remaining rest-monomers from incomplete polymerization
and other leachable components, such as degradation products,
auxiliary products and plasticizers. They require intensive testing of
polymers before transfer to clinical application [46]. Another
frequent issue of polymers is the restriction in modes for sterilization,
as the polymer or conjugated bioactive molecules may not withstand
the high temperature of steam sterilization, the crosslinking potential
of ethylene oxide sterilization or energetic irradiation.
2. Inherent properties of synthetic polymers used in
biomedical ﬁeld
Fig. 1 sketches the basic structures of the main polymer types
used in medicine, and Table 1 contains the polymer abbrevia-
tions used in the text.
2.1. Polyoleﬁns
The polyoleﬁns polyethylene (PE) and polypropylene (PP) are
very inert and hydrophobic materials, which do not degrade
in vivo. PE is produced at different molecular weights and
different crystallinity. Low density PE (LDPE) with molecular
weight 50,000–200,000 and 40–50% crystallinity is most soft with
elastic modulus 100–500 MPa and has application mainly inpackaging. High density PE (HDPE) can have similar molecular
weight but crystallinity of 60–80% and E-modulus of 400–
1500 MPa; it is used to form stable devices as containers or also
for implantation. Ultrahigh molecular weight PE (UHMWPE) has
molecular weight above 2,000,000, 50–60% crystallinity and
elastic modulus of 1000–2000 MPa. Its main applications are
sliding surfaces of artiﬁcial joints. PE can undergo oxidation,
especially gamma sterilization, which increases hydrophilicity,
recrystallization and makes the polymer more brittle.
PP shows similar biological inertness as PE. Its main
application is for suture materials and meshes.
2.2. Poly(tetraﬂuoroethylene) (PTFE)
PTFE (Teﬂons) has an ethylene backbone with four covalently
bound ﬂuorine molecules. Its expanded, porous form with
interconnecting ﬁbrils is called ePTFE (Gore-Texs). It is a highly
hydrophobic, non-degradable material. It induces only little
inﬂammation in the body and shows some tissue ingrowth [47].
It is mainly applied as vascular graft.
2.3. Poly(vinyl chloride) (PVC)
PVC has an ethylene backbone with one covalently bound
chlorine. Its fabrication and application requires stabilizers and
plasticizers, which are the main reason for medical concerns
against this polymer. Stabilizers, most frequently Ca/Zn are
necessary to prevent autocatalytic cleavage of HCl and degrada-
tion of the polymer during thermal processing [48]. Plasticizers,
most frequently phthalates, turn the rigid PVC to a soft polymer,
which is used for extracorporeal tubings or blood storage bags.
Direct cytotoxicity in vitro has been reported for the combination
of tin-based stabilizers and phthalate based plasticizers [49].
There are concerns about phthalate plasticizer di(2-ethylhexyl)
phthalate (DEHP), which presents a high amount of the PVC, is
released to the ambience and dissolves in the lipid bilayers of
cells. Hormone-like effects, birth defects and infertility have been
described for DEHP in rodents. These toxic effects were observed
upon oral uptake, but not upon parenteral administration, because
enteral lipases are seen necessary for toxiﬁcation of DEHP [50].
Published data on complement activation of PVC with
various plasticizers or alternative tube materials are contra-
dictive, but DEHP plasticized PVC apparently activates more
complement than reference materials [51–53]. Also the coa-
gulation activation via the contact system is slightly elevated
for PVC [52,54].
2.4. Silicone
Silicones consist of an –Si–O– backbone with different
chain lengths and crosslinks, which determine mechanical
properties from liquid oil via a gel structure to rubber
elastomer. The side chains may be modiﬁed, but in the most
common poly(dimethylsiloxane) (PDMS) they are methyl
groups. Silicones are hydrophobic and biostable elastomers
without need of plasticizers. The biological response differs for
various applications: There is high tolerance in ophthalmologic
M.F. Maitz / Biosurface and Biotribology 1 (2015) 161–176 165applications [55,56], ﬁbrous capsule formation at breast
implants [57,58], and synovitis as late complication in
intraarticular implants [59]. An association with hematologic
cancers and connective tissue diseases is assumed especially
for silicon oil residues [60,61].Table 1
Abbreviations and applications of the polymers in the text.
Abbreviation Full name Application
BTHC Butyryl-trihexyl-citrate Alternative plasticizer of ↗PVC in bloo
DEHP Di(2-ethylhexyl)phthalate Most frequent plasticizer of ↗PVC
DINCH Di-iso-nonyl-1,2-
cyclohexanedicarboxylate
Alternative plasticizer for ↗PVC
ePTFE Expanded PTFE Gore-Texs, used for vascular grafts, sur
EVAL Ethylene vinyl alcohol
copolymer
Hemodialysis membrane component
HDI Hexamethylene
diisocyanate
Diisocyanate for polyurethane formation
HDPE High density PE Stiff polyoleﬁn used for packaging, inne
contour augmentation
HXPE Highly crosslinked PE Obtained by gamma sterilization of ↗U
IPDI Isophorone diisocyanate Diisocyanate for polyurethane formation
LDPE Low density poly
(ethylene)
Soft polyoleﬁn mainly for packaging
PA Poly(amide) Nylon, used as suture material, ligament
membranes
PAN Poly(acrylonitrile) Dialysis membranes
PC Poly(carbonate) biostable polyester for dialysis membran
PCL Poly(caprolactone diol) Diol for polyurethane formation
PDLA Poly (D-lactic acid) Degradable polyester of D-lactic acid, sim
PDMS Poly(dimethylsiloxane) Silicones are highly inert elastomer, used
surgery, intraocular lenses,glaucoma dra
PDS Poly(dioxanone) Degradable polymer, frequently as co-po
PE Poly(ethylene) Stable polyoleﬁn, used as ↗LDPE, ↗H
PEEK Polyether ether ketone Hard stable polymer for orthopedic appl
PEG Poly(ethylene glycol) Hydrophilic linear polymer used as antif
former in dialysis membranes
PEO Poly(ethylene oxide) Antifouling coating of catheters
PEPA Polyester polymer alloy Hemodialysis membrane
PES Polyether sulfone Hemodialysis membrane
PET Poly(ethylene
terephthalate)
Biostable polyester Dacron used for mem
and tendon repair
PGA Poly(glycolic acid) Degradable polyester with similar applic
pHEMA Poly(hydroxyethyl
methacrylate)
Antifouling coating and hydrogel for int
PMMA
PLGA Poly(lactic-co-glycolic
acid)
PLLA/PGA copolymer with similar appl
PLLA Poly(L-lactic acid) Degradable polyester of L-lactic acid for
repair, vascular stents
PMMA Poly(methyl
methacrylate)
Hard methacrylate as bone cement, as in
PMP Poly(methylpentene) Material for oxygenator membranes with
PP Poly(propylene) Polyoleﬁn for containers, suture material
PSf Polysulfone Component of hemodialysis membranes
PTFE Poly(tetraﬂuoroethylene) Inert and hydrophobic polymer with app
PVA Poly(vinyl alcohol) Linear hydrophilic polymer as antifoulin
pulposus or vitreous body replacement
PVC Poly(vinyl chloride) Low-cost, highly plasticized polymer for
PVDF Poly(vinyliden ﬂuoride) Suture material or surgical mesh
PVP Poly(vinylpyrrolidone) Hydrophilic, soluble polymer as antifoul
SIBS Poly(styrene-b-
isobutylene-b-styrene)
Coating of drug eluting stents
UHMWPE Ultrahigh molecular
weight PE
Stable and low friction polymer for join2.5. Methacrylates
Methyl methacrylates polymerize to very rigid polymers
(PMMA) by radical polymerization and therefore ﬁnd applica-
tion in dentistry and in orthopedics. They are used forRef.
d bags [76]
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process is exothermic and can cause tissue damage, so that low
amounts should be applied and saline irrigation for cooling may
be necessary. While the polymer is biologically inert, there can
be reactions against the monomer and rest-monomers in the
polymer [62]. Due to the optical properties (Plexiglasss) and
inertness in the eye, they are also used as intraocular lenses.
The hydrophilic side chains in the hydroxyethyl methacry-
late monomer lead to the polymerization to a hydrogel
(pHEMA). This has good protein repellant anti-fouling proper-
ties and is used for various applications like hemocompatible
coatings [63,64] or as lubricant coating on contact lenses [65].2.6. Polyesters
Biostable and biodegradable polyesters are used in biomedi-
cine. Biostable polyesters containing aromatic groups are poly-
carbonates (PC), poly(ethylene terephthalate) (PET, dacron).
They are used in form of membranes, ﬁlaments and meshes.
Polyesters of small aliphatic glycolic acid or lactic acid present
the most common degradable polymers poly(glycolic acid)
(PGA), poly(L-lactic acid) (PLLA) and poly(D-lactic acid)
(PDLA). Polydioxanone (PDS) is a further degradable polyester
composed of multiple repeating ether-ester units. Non-enzymatic
hydrolysis of is the main mode of degradation of these polymers,
and the degradation products catalyze the further degradation
[8,11,66]. The degradation rates partly depend on the monomer
structure, but it is also highly inﬂuenced by molecular weight,
crystallinity, ﬁber structure and substituting groups [17]. PGA,
PLLA, and PDLA rapidly entered clinical application because
their monomers and degradation products are physiological
metabolites, however, there are sometimes concerns about the
acidic character of these degradation products causing restrictions
in the permitted amount [11,67]. These polymers are available in
different shapes from solid body for orthopedic applications, via
meshes to drug eluting coatings on vascular stents.2.7. Polyethers
Ether bondings are biostable. Polyether ether ketone (PEEK)
as hard material for orthopedic applications [68] and polyether
sulfone (PES) for dialysis membranes [69] are main representa-
tives of this polymer class in biomedicine.2.8. Polyamides
Naturally, all proteins consist of units liked by amide bonds,
and highly repetitive proteins like collagen or silk ﬁbroin can
be classiﬁed here. The most important synthetic polyamide
with clinical application is nylon. For its high tensile strength it
is used for suture materials. Polyamide block copolymers
containing soft segments for better elasticity combine the
ﬂexibility of polyurethanes with the strength of nylon and
therefore became the material of choice for the balloon of
catheters for angioplasty [70,71].2.9. Polyurethanes
Polyurethanes are synthesized with multiple chemistries
and properties. Polyester-, polyether-, and polycarbonate-
based polyurethanes with aromatic or aliphatic compo-
nents are in medical use, where aromatic formulations
have the better biostability. Thermoplastic polyurethanes
do not need plasticizers, but retain their elasticity by the
mixture of hard and soft segments. The polycarbonate
based polyurethanes have excellent stability against oxi-
dation and biodegradation as PVC does, however, there
are concerns about release of bisphenol A with estrogen-
like activity. Polyether based polyurethanes, especially
aliphatic formulations show rapid softening in the body,
making them more comfortable for the patient [72].
After these general statements about possibilities and trends of
polymers in biomedicine, in the following some speciﬁc
applications shall be reviewed. Due to the plethora of applica-
tions and materials, this review is restricted to main materials, the
speciﬁc demands of the various applications and the approaches
to solve them. Review articles, given in the references have more
in depth information.
3. Biomedical applications of polymers outside the body
3.1. Containers
Numerous polymer devices are not inside the body, but they are
used for packaging of drugs and devices. Plastic ampullas and
preﬁlled syringes are convenient to use, but adsorption and
migration of the bioactive substance into the polymer, pH shifts,
oxygen permeation, optical properties and the release of leachable
components have to be considered carefully for the individual
applications [46,73]. The interaction may affect not only the drug,
but also the function of the polymer container. Polyoleﬁns, HDPE
or PP are the most frequent polymer for compressible vials, but
frequently also multilayer containers are used to achieve required
properties of inertness, oxygen- or UV protection. For preﬁlled
polymer syringes, cyclic oleﬁn polymers and copolymers (Daikyo
Crystal Zeniths) found wide application due to their mechanical
and optical properties, inertness and stability at steam sterilization;
the stopper and the tip cap are usually made of elastomers [73,74].
PVC containing the phthalate plasticizer DEHP is used for
many extracorporeal perfusion tubes to provide medicines, or also
in blood leading tubes in extracorporeal dialysis or extracorporeal
oxygenation. Also blood donations and blood products are
typically stored in bags of this polymer. Due to the lipophilic
nature of the plasticizer, it transfers from the polymer surface to
the lipids and membranes of the red blood cells. It was found that
the plasticizer in the blood bags reduces the hemolysis of red
blood cells by about 50% compared to non-plasticized blood
containers and improves the quality of the blood product [50].
Because of the intense contact and elevated thrombogenicity of
PVC, tubings of extracorporeal circulation therefore are fre-
quently heparinized to reduce the coagulation [75].
In reaction to the phthalate concerns, alternative plastici-
zers partly are applied for storage of red blood cells, such as
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anedicarboxylate (DINCH) [50,76]. For platelet storage,
also alternative polymers like polyoleﬁns are used [77],
and polyethylene and polyurethanes are used for tubings.
The tubings of the peristaltic pumps are typically made of
silicone.
3.2. Hemodialysis membranes
Hemodialysis membranes are produced as bundles of hollow
ﬁbers with a blood contacting surface of 1.0–1.5 m2. Besides
the technical requirements of permeability for substances
smaller than albumin and the request to prevent the passage
of impurities of the dialysate into the blood, the intense blood
contact poses high challenges on the blood compatibility of the
membranes. Early dialysis membranes were made of cellulose,
where hydroxyl groups were soon substituted by acetyl
derivatives or modiﬁed with other supportive additives to
prevent activation of the complement system and associated
leukocyte activation and leukocyte sequestration into the lung
[78–80].
Synthetic membranes mainly are composed of a hydropho-
bic base material and hydrophilic components; the co-
precipitation membranes of polyarylsulfones, polysulfone
(PSf) or PES and polyvinylpyrrolidone (PVP) are most
prominent. But also multiple other membrane materials are
used, such as polyamide (PA), polycarbonate (PC), and
polyacrylonitrile (PAN), PMMA, polyester polymer alloy
(PEPA), ethylene vinyl alcohol copolymer (EVAL), and
molecular-thin nanoporous silicon membranes [81–84]. The
hydrophilic component PVP or poly(ethylene glycol) (PEG) in
the membrane is pore-forming agent and also improves
antifouling properties and blood compatibility.
The process of removal of uremic substances during hemodia-
lysis is controlled by diffusion along concentration gradients,
pressure gradients (convection) and adsorption to the membrane.
Thus, effective pore size, low membrane thickness and binding
capacity for uremic substances determine the efﬁciency of a
membrane. Especially PMMA membranes have high binding
capacity for β2-microglobulin or for activated complement factors
and prevents their entry into circulation [81,85]. A most narrow
distribution of the pore size has to be achieved to provide a sharp
cut-off only slightly below albumin 50–60 kDa [86].
3.3. Extracorporeal membrane oxygenation
Membranes for extracorporeal membrane oxygenation,
ECMO have slightly different mode of action than dialysis
membranes. In order to achieve good exchange of O2 and
CO2, microporous hollow ﬁber membranes of hydrophobic
PP with pores of less than 1 μm diameter are applied
[87,88]. Gas transfer occurs at a direct blood-air interphase
at these pores, guaranteed by the interface tension at the
highly hydrophobic material, however, protein adsorption
and water evaporation changes the interphase properties
and plasma leakage happens. Recently membranes of
polymethylpentene (PMP) have been developed, whichhave a very thin ﬁlm covering the pores, thus avoiding
problems of pore occlusion by deposited proteins or plasma
leakage and therefore do not require round-the-clock
monitoring by a perfusionist or respiratory therapist
[89,90]. Silicon hollow ﬁbers as pore-free membranes with
good gas permeability and good hemocompatibility pro-
mise further safety of plasma and gas leakage, however,
they are still in an evaluation phase [91,92].4. Temporary in vivo applications
4.1. Vascular catheters
Vascular catheters must be non-thrombogenic and must not
induce an inﬂammatory response in the vessel wall. Mechan-
ical ﬂexibility along with non-kinking and non-collapsing
properties is required. Central venous catheters with longer
persistence in the body usually have antimicrobial ﬁtting and
properties which prevent the formation and adhesion of
bacterial bioﬁlms.
Plasticized PVC was one of the ﬁrst polymers used for
catheters. It is mainly avoided nowadays due to the plasticizers
and is used only for short-term applications as peripheral
venous catheters. Thermoplastic polyurethanes are the key
polymers for catheters as they do not need plasticizers.
Multiple polyester-, polyether-, and polycarbonate-based poly-
urethanes with aromatic or aliphatic components have been
prepared for catheter application [71,72]. Silicone vascular
catheters are inserted for long term access (weeks to months),
frequently as access for hemodialysis. Silicon is softer than the
polyurethanes, therefore also thick-lumen catheters have no
risk of vascular injury [93].
The surface of the catheter may be modiﬁed by grafting long
chain hydrophilic molecules like PEG or exposing them from
the bulk polymer to reduce protein adsorption. Active antic-
oagulant properties frequently are endowed by immobilization
of heparin with various methods. Antimicrobial properties are
provided by incorporation of silver nanoparticles, silver
sulfadiazine, chlorhexidine or others [94–96].
HDPE or PTFE are usually used as inner lining of
interventional catheters to provide good sliding on the guide
wire. Guide wires also may be PTFE coated. Alternatively,
polyimide or PEEK is used as inner lining of load bearing
catheters due to their high mechanical resistance. Polyamide
block copolymers are frequently used as the outer layer of
these catheters, because they combine the ﬂexibility of
polyurethanes with the strength of nylon [70]. The balloons
of interventional catheters are typically made of polyester or
the polyamide nylon 11 and nylon 12 due to their tensile
strength. The catheters usually get a lubricant surface ﬁtting to
improve the placement.
4.2. Urinary catheters and ureteral stents
Urinary catheters are mostly made of latex, polyurethane or
silicone. Due to a high prevalence of latex allergy and the high
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General problems with urinary catheters are urinary tract infec-
tions, catheter incrustation and blockage, which also is promoted
by colonization with bacteria Proteus mirabilis and damage of the
mucous membrane of the urinary tract [97–99]. The catheter must
have sufﬁcient strength to allow insertion, prevent occlusion by
kinking or collapse and allow removal without detachment of the
balloon from the shaft, but be sufﬁciently soft for the tolerance of
the patient. The surface must be smooth with a low friction ﬁnish.
Coating technologies therefore are generally applied.
Latex catheters coated with PTFE may stay in the patient up to
4 weeks, silicon catheters or silicon coated latex even longer. Also
hydrogel coatings, e.g. of pHEMA allow long maintenance of the
catheter. Antimicrobial ﬁttings are provided by silver containing
hydrogel coatings or nitrofurazone or minocycline/rifampicin
impregnation. Although these systems could decrease the risk of
minor contamination, results are disappointing concerning sympto-
matic infections in clinical studies [100–103]. Copolymerization of
acrylate polymers with different aliphatic and aromatic structures
recently showed promising antimicrobial results in vitro and
in vivo, which await transfer to clinics [104].
Polymer ureteral stents in the upper urinary tract face similar
problems of bacterial infection and encrustation with signiﬁcant
morbidity as the catheters in the lower urinary tract [105,106].
Silicone is the best biocompatible material with lowest tendency
for encrustation, but low mechanical stiffness and high friction
make application difﬁcult. Optimized polyurethane formulations
(Perculfexs, Tecoﬂexs, Hydrothanes, ChronoFlexs, Sof-
Flexs), polyester (Siliteks), polyethylene-vinyl acetate and
Styrene/ethylenebutylene/styrene block copolymers (F-Flexs),
and PMMA/pHEMA co-polymers have been developed as
polymers with improved mechanical properties than silicone.
Stents are coated with glycosaminoglycanes (GAGs, heparin or
pentosan polysulfate), phosphorylcholine, PVP or hydrogels for
reduced bacterial coloninzation, encrustation and enhanced
comfort for the patients [105,106].
4.3. Wound dressings
Wound dressings are a very wide ﬁeld for polymers in temporary,
mainly external contact with the body. Wound healing is a complex
biological process, involving inﬂammation, clearing of cell debris,
cell migration, proliferation and differentiation, and remodeling
which may be disturbed at different steps in the case of delayed
wound healing of chronic wounds. Advanced active polymer wound
dressings have been developed with release or adsorption properties
to support physiological processes or remove detrimental inﬂuences.
They are also more comfortable for the patient than traditional gauze
dressings [107–109]. Mechanical protection and a barrier function
are achieved with minimized adherence to the wound avoiding
traumatization during movements or removal. The dressing has to
provide permeability for oxygen and water vapor for a proper
ambient of wound healing without bacterial superinfection. Hemo-
static properties are preferred for the wound dressings, especially in
the case of hemorrhagic traumatization [109].
A wide range of synthetic, biological and hybrid materials are
applied in multiple shapes to match different types of wounds[110]. Transparent semipermeable ﬁlms of nylon, polyurethanes
with acrylate based coatings or natural polymers like chitosan
provide a mechanical protection and barrier with support of a
moist environment at the wound, but they are not suitable for
infected or heavily exudating wounds [107,111]. Foam dressings
of synthetic polyurethane foams or natural polysaccharide alginate
foams are highly absorbing and permeable for water vapor and
they are therefore recommended for exudating wounds. Hydro-
colloids are a combination of hydrogel forming components like
carboxymethyl-cellulose, gelatin, pectin, alginates and elastomers,
which provide the mechanical stability. They are suitable for
moderately exudating wounds and can be ﬁtted also with drug
release properties for antimicrobials, antibiotics or growth factors.
Pre-swollen hydrogels of collagen or elastin, hyaluronic acid,
alginate, chitosan, or synthetic hydrogels of PVP or methacrylates
as wound dressing are highly ﬂexible, but usually need a
mechanical support. As they do not absorb much liquid any more,
they are not suitable for heavily exuding wounds, but they
rehydrate dry tissue, facilitate autolytic wound debridement and
also may be used for drug release.
5. General surgical implants
5.1. Suture materials
Suture materials and staples are a domain of polymers in
general surgery. Tensile strength, friction/trauma to tissue,
degradability and stability of knots are main parameters for
the selection of suture materials. Still a number of biological
suture materials is in use. Degradable biological suture materials
are collagen based materials, catgut; non-degradable bio-poly-
mers are silk or cellulose (cotton). Synthetic resorbable materials
are PGA, polyglactic acid (Vicryl), PDS, poliglecaprone 25
(Monocryl); non-resorbable suture materials are nylon, poly-
ethylene, polypropylene (Prolene), polyester, polybutester, and
Polyvinylidenﬂuorid (PVDF) [112]. Generally fast healing
tissue, such as peritoneum and inner organs is treated with
resorbable suture material, whereas slow-healing tissue and
tissue with high mechanical exposure, such as skin or tendons,
are treated with non-resorbable material. The biological degrad-
able materials degrade by proteolysis with signiﬁcant tissue
response, whereas hydrolytically degrading synthetic polymers
show less tissue response. Also for the non-resorbable suture
materials, the biopolymers silk or cotton cause more intense
inﬂammation than the synthetic polymers [113].
5.2. Tissue adhesives and sealants
Tissue adhesives are an alternative to sutures with lower
adhesion strength than sutures, but forming an a priori tight
occlusion of the wound [114,115]. Adhesives ﬁnd wider
application in modern surgical techniques of laparoscopy and
robotic surgery or for organs like liver or lung, where the
puncture defects of the needle are already problematic. A
technological challenge is the adhesion to the wet substrate.
The main biological sealants are ﬁbrin glues with the main
two components ﬁbrin and thrombin mixed at the site of the
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prevents ﬁbrinolysis. However, there are also collagen-,
gelatin-, and polysaccharide- (chitosan, alginate, heparin or
chondroitin sulfate) based adhesives [116–118]. Due to the
limited strength of these adhesives, they are mainly used to
prevent bleeding and they are combined with sutures. Cyana-
crylate glues (2-octyl cyanoacrylate, n-butyl-2-cyanoacrylate)
are the most frequently applied synthetic glues, mainly in
superﬁcial wounds in cosmetic surgery to avoid stitches. They
provide higher strength than the ﬁbrin glues. Photopolymer-
ized PEG-based hydrogels ﬁnd application for bigger wounds
in thoracic surgery. Dendrimers with reactive end groups have
application in ophthalmic surgery. Polyurethanes of polyca-
prolactone diol (PCL) either with isophorone diisocyanate
(IPDI) or with hexamethylene diisocyanate (HDI) are fully
degradable tissue glues [119], however the curing time of the
polyurethane adhesives and sealants usually is too long for
practical application [116]. Due to the adhesion to wet
surfaces, even mussels and mussel-inspired adhesive found
attention [116].5.3. Surgical meshes
Reconstructive meshes in general surgery support organs or
tissue to prevent a prolapse or hernia. The main classiﬁcations
of the surgical meshes are according to the mash size or the
weight of the mesh, because this is more relevant for the
biological response than the material [120,121]. The main
polymers for non-resorbable meshes are expanded PP, ePTFE,
PET or PVDF, however, also they show signiﬁcant signs of
degradation at the surface and even fragmentation. Among
these materials PVDF meshes usually induce less foreign body
response than PP meshes do [122,123]. Large pores (o1 mm)
generally show less inﬂammation and bridging scare formation
than small pores do.6. Orthopedic implants
6.1. Joint prostheses
In orthopedic surgery, joint prostheses most frequently have
a pairing of metal on UHMWPE [124]. UHMWPE is a
semicrystalline polymer with superior strength, creep- and
wear resistance; however, it still is the weaker component of
the pairing due to wear, oxidation and fatigue fractures. Long
lived free radicals in the polymer induced by gamma steriliza-
tion caused signiﬁcant ageing of the UHMWPE devices upon
storage in oxygen containing ambience. While other means of
sterilization are possible, gamma sterilization is generally
preferred, because it induces crosslinkings and improves the
mechanical stability of the polymer [125,126]. This highly
crosslinked PE is referred to as HXPE. Antioxidants, like
vitamin E are added to the UHMWPE to quench free radicals
and improve mechanical properties as a plasticizer [127].Sub-micrometer debris particles are the main problem of
UHMWPE, as they induce a chronic inﬂammation, bone
resorption, osteolysis, and loosening of the implant [128,129].
No other polymer could take the role of UHMWPE for
replacement of big load bearing joints; there are only metal-on-
metal or ceramic-on-ceramic pairings as alternatives. In small
joint replacement ﬂexible silicon spacers dominate [130].
However, inorganic pyrolytic carbon (Pyrocarbon) with
graphite-like structure ﬁnds increasing attention for small
joints or as interposition material because of its inertness,
low friction behavior and a Young's modulus close to bone
[131,132].6.2. Osteosynthesis material
Stabilizing and load transferring applications at bone must
be strong enough to withstand the forces, but they also should
have elastic properties similar to the bone for a homogeneous
load transfer and to prevent stress shielding of the bone, which
would lead to bone resorption. Cortical bone has a Young‘s
modulus of about 20 GPa [133]. Most metals have a higher
modulus, but carbon ﬁber reinforced polymer composites can
reach such values and therefore they are applied for some load
bearing applications. A technical disadvantage of thermoset
reinforced polymers, like epoxy resins, is that they cannot be
contoured to the bone in the way as metal plates can, and there
are concerns about leachable toxic rest monomers [134,135].
However, especially carbon reinforced PEEK is attractive and
has application in spine surgery for fusion cages [68];
applications as osteosynthesis plates and endosseous nails of
PEEK are in more experimental stages [68,134–138]. Poly-
lactide based resorbable osteosynthesis plates also have been
developed. Due to low mechanical strength, completely
resorbable polymers are applied only at non-weight bearing
bones in maxillofacial surgery. Reinforcement with phosphate
bioglass ﬁbers gives higher strength to expand the application
spectrum [134].
Vertebral disc replacement may be necessary in the case of a
disrupted or degenerative intervertebral disk. Either only the
nucleus pulposus needs to be substituted or the total disc.
While total disk replacement mainly is done by mechanical
joint pairings [139,140], silicone elastomers and polyvinyl
alcohol (PVA) hydrogels or PVA–PVP co-polymers are
applied for nucleus pulposus replacement. They may be
inserted as solid piece or injected and cure in situ [141,142].6.3. Bone cements
Bone cements serve for anchorage of a joint prosthesis
into the bone and should provide a homogeneous load
transfer from the implant to the bone. PMMA is widely
predominant for this application [143]. It is frequently
equipped with the antibiotic gentamicin [144]. As PMMA
does not promote bone adhesion, ﬁlling with hydroxyapatite
particles has been suggested [145]. The polymerization
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tissue damage. There are also concerns about the toxicity of
monomers released during this phase. Zinc-based glass
polyalkenoate (glass-ionomer) cements [146] lead to bone
resorption and ﬁbrous encapsulation and therefore are not
suitable for general application. Calcium phosphate cements
have excellent biocompatibility, but the mechanical proper-
ties do not allow application in load bearing situations; the
main applications are in dentistry and cranial surgery [147].
6.4. Scaffolds for ligament and tendon repair
Various materials are used to bridge ligament and tendon
defects where autologous material is missing or not strong enough
[148]. Mammalian collagen scaffolds, obtained for small intestine
submucosa, dermis, pericardium, kidney capsule or other tissues
by intensive cleaning and removal of cellular components, cross-
linking and sterilization are frequently used biopolymers for this
purpose [148,149]. They contain more than 90% type I collagen,
some type III collagen and elastin. Their mechanical stability is
relatively low, even causing failure of surgery, but they have the
clear advantage of interaction with the host tissue, cell adhesion,
proliferation and matrix remodeling. Synthetic polymers for
ligament or tendon repair are polypropylene, ePTFE, PET/Dacron,
nylon. They provide better mechanical stability than the biological
scaffolds, however their non-degradation and persistence in the
body causes problems [148]. Foreign body reactions, inﬂammatory
responses and synovitis are frequent [149]. A biodegradable
polyurethane urea polymer (Artelons) as a degradable synthetic
scaffold material is on the market [150], resorbable polylactic acid
and poly (lactide-co-glycolide) (PLGA) scaffolds are in an
experimental phase [148]. However, the main developmental work
in ligament or tendon repair is in the ﬁeld of tissue engineering.7. Vascular and cardio-vascular intervention
7.1. Vascular stents
Vascular stents in conjunction with balloon angioplasty have
revolutionized angiology and cardiology as they maintain blood
ﬂow through stenotic vessels. First stents were only metal supports,
partly with hemocompatible ceramic or inorganic carbon coatings
[151–153]. With the appearance of drug eluting stents, which
combat responsive proliferation of the vessel wall and restenosis of
the target vessel, polymers came up as release platform. The
coatings of ﬁrst generation drug eluting stents were a polymer
blend coating of poly(ethylene-co-vinyl acetate) and poly(n-
butylmethacrylate) loaded with sirolimus or poly(styrene-b-isobu-
tylene-b-styrene) (SIBS) loaded with paclitaxel, respectively. Both
polymer coatings were thick with 12–16 mm, not degradable and
did release only a small fraction of their drug cargo [154]. They
were also not optimized for blood compatibility, attributing to the
problem of late stent thrombosis. The second generation stent
coatings were everolimus eluting ﬂuoropolymer or zotarolimus
eluting phosphorylcholine methacrylate with thickness of only
5–8 mm [155]. There is modiﬁcation of the release kinetics bydrug-free top-layers. Coating technologies, which treat only the
abluminal stent surface, prevent blood clotting by a non-
hemocompatible polymer coating. Degradable polymers in use
for drug eluting coatings are PLLA, PLGA block copolymers, or
poly(lactide-co-S-caprolactone) copolymer [154,156].
Fully degradable stents, which vanish after the blood vessel
has sufﬁciently remodeled are mostly made of the metals
magnesium and its alloys or iron [16]. However, there are
also polymer stents which can be fully degraded and
metabolized by the body made of PLLA, PGA and their
copolymer, PLGA. They have typical strut thickness of
170 mm and resorption time of 1–3 years [16]. The resorption
time can be controlled by various factors like molecular
weight and crystallinity of the polymer. While the perfor-
mance of early polymer stents, either stable or degradable
was poor due to different geometry, bio-incompatibility of the
polymers and their degradation products [157], this has
improved remarkably for drug eluting fully degradable stents
[158]. As acidic degradation products induce inﬂammatory
vessel wall response [157], there are concepts to quench them
by incorporation of calcium phosphate nanoparticles [159].
7.2. Vascular grafts
Vascular graft materials are used as vascular prosthesis in
aneurysm surgery, fur bypass surgery or as hemodialysis access.
ePTFE has evolved as the leading material for this application
[160,161]. Although graft patency is similar to the polyester
Dacron, ePTFE has handling advantages [161,162]. Vascular
access grafts of polyurethane are self-sealing and therefore allow
immediate puncture in contrast to ePTFE grafts. They show
similar patency as ePTFE grafts, but the rate of infectious
complications is higher [163–165]. Although polymer vascular
grafts for big vessels are rather successful, 5-year patency rates
e.g. of femoropopliteal bypass grafts are only in the range 40–
50% [162]. The patency of small caliber vessels is even less,
and there are still no successful synthetic grafts below 6 mm
diameter. Autologous venous grafts, despite defects at the donor
site therefore are still ﬁrst choice for bypass or hemodialysis
vascular access. Tissue engineering of endothelialized vascular
grafts for small diameter vessels or vessels, which can remodel
and grow, is a major ﬁeld of research [166].
7.3. Polymeric heart valves
There are two main types of artiﬁcial heart valves, either
mechanical tilting disk-and-ring constructs of metal or pyrolytic
carbon or bioprosthetic valves made of decellularized and cross-
linked porcine heart valves or bovine pericardium. The mechan-
ical valves have better long-term stability than the bioprosthetic
valves, but they require permanent anticoagulation of the patient
[167]. There are only few studies of polymer prosthetic heart
valves [168,169]. Thermoplastic polyurethanes, polycarbonate
urethanes and polysiloxane-based polyurethanes provide good
ﬂexibility at low thrombogenicity and resistance to degradation
or calciﬁcation [170]. However, still blood clotting and dete-
rioration of the polymer valves by calciﬁcation are the leading
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applications in cardiac assist devices [170].
8. Plastic, reconstructive and cosmetic surgery
Reconstructive surgery applies the surgical techniques and
materials described before for the general and orthopedic
surgery. Tissue augmentation for the correction of contour
deﬁciencies is a speciﬁc domain of plastic surgery. Crosslinked
silicone elastomer is used as onlay material on bone and soft
tissue for contour augmentation, in chin and malar cosmetic
surgery. For breast implants or tissue expanders, silicone
elastomer is usually the outer shell of saline or silicone-gel ﬁlled
implants. There is chronic inﬂammation around the implant with
ﬁbrous encapsulation and potential association with anaplastic
large cell lymphoma [58,171]; the mechanism of this encapsula-
tion is still not completely clear, but a textured surface seems to
reduce the encapsulation and contracture [57,172].
A HDPE with interconnected pores (Medpor) is typically
used for craniofacial contour augmentation and restauration
of nose, orbital rim and ﬂoor and also for ear reconstruction
[173]. Vascular and ﬁbrous tissue ingrowth provides integra-
tion and ﬁxation of the implant [47]. Also ePTFE is used as
facial augmentation material [174].
9. Ophthalmology
9.1. Contact lenses
Contact lenses are the most frequently applied biomaterials on
the eye. In the contact with the eye, the material must be
sufﬁciently hydrophilic to sustain the normal hydration of the tear
ﬁlm and resist deposition of tear proteins and lipids. Early polymer
lenses were made of rigid PMMA, being hard and oxygen
impermeable, both properties are harmful to the cornea epithelial
cells [175,176]. The introduction of silicon acrylates allowed the
formation of rigid gas permeable contact lenses. Siloxane contain-
ing hydrogels are used for the formation of soft oxygen permeable
contact lenses for up to one month permanent wear [176]. Such
hydrogel contact lenses are currently also considered as drug
release systems, e.g. in the treatment of glaucoma [177].
9.2. Intraocular lenses
Intraocular lenses (IOLs) after cataract surgery are the most
frequently implanted polymer devices in ophthalmology.
They traditionally were made of PMMA, and this material
still has outstanding biocompatibility for this application;
however, due to its stiffness these lenses need large incisions
for implantation, and they are less frequently used today.
Alternatives are silicone, foldable hydrophobic acrylates,
copolymers of acrylate and methacrylate or foldable hydro-
philic acrylates, mixtures of pHEMA and acrylic monomers.
Also biohybrid polymers, containing collagen (Collamer) are
available with good biocompatibility [56,178]. All lenses areequipped with a chromophore to absorb UV light; some also
absorb blue or violet light to protect the retina [179]. Highly
hydrophilic poly(ethylene oxide) (PEO) as antifouling coat-
ings, but also ﬂuorinated omniphobic coatings are applied
on lenses to reduce cell adhesion and opaciﬁcation [178].
Stability to silicon oil, which may be used for ocular
endotamponade in vitrectomy surgery, tendency for opaciﬁ-
cation of the posterior capsule and opaciﬁcation by calciﬁca-
tion are issues to consider [56].9.3. Other polymer devices in ophthalmology
In the frame of retinal detachment treatment, the vitreous
body of the eye is generally removed and needs to be
substituted. Gases octaﬂuoropropane and sulfur hexaﬂuoride
are most frequently used for this. Silicon oil is the most
frequently used polymer for it and it is the ﬁrst choice for
complex retinal detachment, however, it must be removed after
healing because of side effects like retina toxicity, cataract
progression and glaucoma [180,181]. Hydrogels of crosslinked
PVA, PVP, PEG, and poly(acrylamide) and also responsive
hydrogels have been suggested, but there is no long-term
experience yet [177,181].
Glaucoma drainage implants are inserted to drain the
anterior eye chamber in cases where glaucoma is refractory
to medical treatment and trabeculectomy. Materials are poly-
propylene, polyethylene, or silicone, where silicone seems to
be associated with less complications [55,182].10. Dentistry
10.1. Composites
Dental polymers have high requirements concerning
esthetics, toughness, and polymerization mode besides the
biocompatibility. Materials must support high load and shear
forces, and forces of thermal expansion and shrinkage. As
mentioned before, leachable unreacted monomers deteriorate
the biocompatibility. Polymerization associated shrinkage has
to be avoided for tightness of the ﬁlling. Composite ﬁlling
materials consist of polymerizable resin, ﬁller, and the ﬁller–
resin interface. [183–185]. The ﬁller is usually inorganic with
particle size in nanometer or micrometer range. It increases the
modulus of the polymerized composite, modulates the tem-
perature behavior and the polymerization shrinkage. Usually
ﬁllers are silanized for improved bonding in the polymer
network. The resin usually consists of dimethacrylate or
monomethacrylate monomers, and different formulations with
different viscosity, curing time, improved volume shrinkage
and shrinkage stress are the current developments [185]. Free
radical addition polymerization with photoinitiation is the
mostly applied [183], but self-curing one- or two compo-
nent systems are still in use and have advantages for certain
applications [186].
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11.1. Peripheral nerve guidance conduits
Nerve guidance conduits are used for the repair of peripheral
nerve damages, where direct repair by neurorrhaphy is not
possible and where the gap should not be bridged by an
autologous graft. The conduit provides mechanical stability; it
guides the axonal sprouting and prevents ﬁbrous tissue
ingrowth. Stability, ﬂexibility and guidance properties by 3D
tubular structure are basic requirements. The materials must be
semipermeable to allow passage of oxygen, nutrients and
metabolites, but maintain a milieu of neurotropic factors.
While there is still big research in this ﬁeld, several conduits
have received FDA approval and are in clinical use [187].
Processed and decellularized allograft nerve tissues with
removed immunogenicity but maintained extracellular matrix
components and growth factors are commercially available as
biological grafts [67,188–190]. Tubular sheaths of PVA
hydrogel are used as synthetic non-resorbable conduits and
allow bridging up to 6.35 cm, however, neural compression
can occur due to the lack of absorption [67,191]. Resorbable
PGA is the most widely used material for conduits and has
indication for bridging of defects up to 3 cm, although there
are concerns about the acidic degradation products [67]. Poly
(D,L lactide-co-ε-caprolactone) is a successor product with
slower degradation and less acidic degradation products and
got approval for tubes up to 10 mm diameter. It has advantage
of transparency, but disadvantage of high stiffness [67,190]. In
the ﬁeld of biopolymers, various devices with type I collagen
are on the market suitable for gaps up to 4 cm [67]. Agarose,
chitosan, keratin, silk or synthetic poly(hydroxybutyrate) or
polyurethanes are experimental polymers for nerve guidance
conduits [192–194].
11.2. Central nervous system
Possibilities for regeneration in the central nervous system
are much more limited than peripheral nerve repair because of
the high complexity. However, there are various approaches to
regenerate the dopaminergic cells of the substantia nigra using
hydrogels as scaffold material [195–198]
12. Conclusion
Numerous types of polymers are currently in use in virtually
all ﬁelds of medicine. The different polymer classes with
tailored formulations like adjusted molecular weight, cross-
linking degree, degree of crystallization, co-polymers and
blends and additional bioactive surface functionalization allow
this wide range of applications. While engineering-related
properties like stiffness, tensile stability and elasticity are
usually primary characteristics for selecting a polymer, also
toxicity and biocompatibility aspects have to be taken into
account. Biodegradation as a more advanced property of some
polymers ﬁnds application in an increasing number of ﬁelds
from suture materials via orthopedic stabilizing materials tovascular stents, because these devices may disappear after they
fulﬁlled their function. Responsive degradation of polymers
upon deﬁned triggers also allows controlled drug release
applications. These concepts currently present the most active
ﬁelds of research and products should soon appear on the
medical device market.References
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